Aptahem (publ), a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved, announces today that the cooperation with the Seattle Children’s Hospital has now generated the...
Read MoreAptahem today informs that the company’s latest patent application has been made public. The patent application, which is an international PCT application*, is a merger of two previous Europe applications with the priority date 3 October 2017. The patent...
Read MoreAptahem (publ) announced today that Dr. Anders Bylock, Chief Medical Officer (CMO), is taking on another part-time position effective immediately. Dr Bylock engagement with the company as CMO as well as chairman of the scientific advisory board is unchanged...
Read MoreAptahem (publ) announced today that manufacture of its drug product has been delayed as a result of technical challenges. As a consequence, Aptahem anticipates that commencement of the planned clinical study for Apta-1 will be delayed. Aptahem reports that...
Read MoreAptahem AB (publ) today announces that the company intends to recall the outstanding amount of convertible notes held by YA II PN Ltd, a fund represented by the U.S.-based Yorkville Advisors Global (”Yorkville”). Through a mutual agreement, Aptahem will...
Read MoreIn the fight to save a person affected by sepsis every second counts – each hour that passes increases the risk of death with 8 percent. It is literally a race against time, a race that the healthcare services...
Read MoreAptahem (publ) announce today that the extended exploratory sepsis study in primates has shown positive results. This increases the hope of being able to show good efficacy also in upcoming and more extensive confirmatory studies. After the company announced...
Read MoreAptahem (publ) announce today that the final reports from the non-regulated GLP (Good Laboratory Practice) toxicology- and safety studies in Apta-1’s pre-clinical program show positive results. The results indicate that higher dosages of Apta-1, than previously estimated, shows a...
Read MoreOn 26 June 2018, Aptahem (publ) signed an issuance agreement with YA II PN Ltd, a fund represented by the United States-based Yorkville Advisors Global (“Yorkville”), which describes the terms of issuance of and subscription to notes convertible into...
Read MoreAptahem AB (publ) announce today that the company’s ongoing pre-clinical toxicology development program is delayed pending the manufacturing of more Apta-1. The drug candidate Apta-1 has in the company’s ongoing toxicology program indicated a good safety profile, which has...
Read More